New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MCK;CAH;ABC;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
07:23 EDTCAHCardinal Health reports Q2 Pharmaceutical revenue up 16% to $22.B
Reports Q2 Medical revenue up 4% to $2.9B.
07:02 EDTCAHCardinal Health raises FY15 non-GAAP EPS to $4.28-$4.38 from $4.10-$4.30
FY15 EPS consensus of $4.26.
07:02 EDTCAHCardinal Health reports Q2 non-GAAP EPS $1.20, consensus $1.10
Subscribe for More Information
January 28, 2015
15:38 EDTCAHNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Celgene (CELG), consensus 99c... ConocoPhillips (COP), consensus 59c... Abbott Laboratories (ABT), consensus 67c... Occidental Petroleum (OXY), consensus 68c... Colgate-Palmolive (CL), consensus 74c... Ford (F), consensus 23c... Dow Chemical (DOW), consensus 69c... Alibaba (BABA), consensus 75c... Thermo Fisher (TMO), consensus $1.94; Time Warner Cable (TWC), consensus $2.09... Phillips 66 (PSX), consensus $1.34... Alexion Pharmaceuticals (ALXN), consensus $1.29... Baxter International (BAX), consensus $1.31... Cardinal Health (CAH), consensus $1.10... Raytheon (RTN), consensus $1.08... Northrop Grumman (NOC), consensus $2.25... Viacom (VIAB), consensus $1.28... Valero Energy (VLO), consensus $1.32... Sherwin-Williams (SHW), consensus $1.38... Hershey (HSY), consensus $1.06... Mead Johnson (MJN), consensus 88c... Zimmer (ZMH), consensus $1.71... Xcel Energy (XEL), consensus 34c... Royal Caribbean (RCL), consensus 42c... Coach (COH), consensus 66c... Kate Spade (KATE), consensus 24c... Harley-Davidson (HOG), consensus 34c... Stanley Black & Decker (SWK), consensus $1.52... L-3 Communications (LLL), consensus $2.27... JetBlue (JBLU), consensus 24c.
11:38 EDTGSKEC clears GlaxoSmithKline, Novartis deals, with conditions
Subscribe for More Information
07:07 EDTABCAmerisourceBergen sees FY15 adjusted EPS $4.45-$4.55, consensus $4.51
Sees FY15 revenue growth 10%-11%, consensus $128.9B. Adjusted operating income growth in the 9 percent to 11 percent range; Flat adjusted operating margin; Free cash flow generation in the range of $1.8 billion to $2.0 billion; Capital expenditures in the $250 million range; Regular share repurchases of approximately $200 million; and Special share repurchases of approximately $400 million. In addition, sees acquisition of MWI (MWIV) will contribute an incremental 8 cents of adjusted diluted earnings per share in the second half of fiscal 2015.
07:04 EDTABCAmerisourceBergen sees MWI Veterinary Supply deal closing in March quarter
Subscribe for More Information
07:04 EDTABCAmerisourceBergen reports Q1 adjusted EPS $1.14, consensus 97c
Subscribe for More Information
January 27, 2015
15:35 EDTABCNotable companies reporting before tomorrow's open
Subscribe for More Information
January 26, 2015
09:19 EDTGSKGlaxoSmithKline announces availability of two new products for asthma
Subscribe for More Information
07:33 EDTABCAmerisourceBergen commences tender offer to acquire MWI Veterinary Supply
AmerisourceBergen (ABC) announced that it has commenced a tender offer to purchase all outstanding shares of MWI Veterinary Supply (MWIV) for $190.00 per share, net to the seller in cash, without interest, less any applicable withholding taxes. The tender offer is being made pursuant to the merger agreement entered into by AmerisourceBergen and MWI and announced on January 12. Unless extended, the tender offer will expire at 11:59 p.m., New York City time, on February 23. The completion of the tender offer is subject to the tender of at least a majority of MWI’s outstanding shares of common stock and other customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
07:05 EDTCAH, MCKNovaBay signs Avenova distribution agreement with Cardinal Health
Subscribe for More Information
January 23, 2015
08:52 EDTGSKArray BioPharma to hold a conference call
Subscribe for More Information
08:10 EDTGSKArray agrees to acquire rights to encorafenib
Array BioPharma (ARRY) announced that it has reached a definitive agreement with Novartis (NVS) to acquire worldwide rights to encorafenib, a BRAF inhibitor currently in Phase 3 development. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline (GSK) on April 22, 2014, which are expected to close in the first half of 2015, and the agreement remains subject to the receipt of regulatory approvals. Array previously announced a definitive agreement with Novartis to regain global rights to the Phase 3 MEK inhibitor binimetinib, the material terms of which remain in place following this agreement. In order to address competition concerns raised by the European Commission, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib. The European Commission is expected to issue a decision regarding the Novartis-GSK transaction on January 28, 2015. Upon satisfaction of all conditions and closing of the deal, Array will acquire global rights to encorafenib. Other than a de minimis payment due to Novartis from Array, there are no milestone payments or royalties payable under this agreement by either party. Novartis has agreed to provide transitional regulatory, clinical development and manufacturing services as specified below and will assign or license to Array all patent and other intellectual property rights Novartis owns to the extent relating to encorafenib. As part of the transaction, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib. If Array is unable to find a suitable partner in the prescribed time period, a trustee would have the right to sell such European rights. Novartis will conduct and fund the COLUMBUS trial through the earlier of June 30, 2016 or completion of last patient first visit. At that time, Array will assume responsibility for the trial, while Novartis will reimburse Array for out-of-pocket costs along with 50% of Array's full time equivalent costs in connection with completing the COLUMBUS trial. Novartis is responsible for conducting all other encorafenib trials until their completion or transfer to Array for a defined transition period. For all trials transferred to Array, Novartis will reimburse Array for out-of-pocket costs and 50% of Array's FTE costs in connection with completing the trials. Novartis will supply encorafenib for clinical and commercial use for up to 30 months after closing and will also assist Array in the technology and manufacturing transfer of encorafenib. Novartis will also provide Array continued access to several Novartis pipeline compounds for use in currently ongoing combination studies, and possible future studies, including Phase 3 trials, with encorafenib. The effectiveness of the agreement is subject to the receipt of regulatory approvals and to the consummation of the Novartis-GSK transaction. In addition, Array agreed to undertake to obtain certain third party consents or waivers necessary for Array to consummate the transactions under the Novartis Agreement.
07:44 EDTGSKGlaxo says now in position to deliver 'tens of thousands' of Ebola vaccine doses
Witty expects to start seeing data from trials of Ebola vaccines in next four to five months. GlaxoSmithKline CEO Andrew Witty speaking on CNBC.
06:39 EDTGSKNIH, GlaxoSmithKline, Merck launch joint Ebola vaccine test in Liberia, WSJ says
Subscribe for More Information
January 21, 2015
12:30 EDTGSKGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use